Global Genetic Obesity Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 100
Published Date: 02 Sep 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Genetic Obesity Drug market size was valued at USD 2726.7 million in 2022 and is forecast to a readjusted size of USD 4186.4 million by 2029 with a CAGR of 6.3% during review period.
Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.
The global genetic obesity drug market refers to the market for medications and therapies used to treat obesity caused by genetic factors. Genetic obesity is a complex condition that arises from various genetic mutations and alterations, leading to an increased risk of excessive weight gain and difficulty in losing weight.
The treatment of genetic obesity focuses on managing weight gain and associated health issues. While lifestyle modifications such as diet and exercise are important in managing obesity, genetic obesity may require additional targeted interventions. Currently, there is ongoing research and development in the field of genetic obesity drugs, with the aim of developing medications that can directly address the underlying genetic causes of obesity.
The global genetic obesity drug market is influenced by factors such as the increasing prevalence of obesity, advancements in genetic research, and the need for personalized treatment options. However, it’s important to note that the market for genetic obesity drugs is still in its early stages, and there are currently limited approved medications specifically targeted towards genetic obesity.
Geographically, the market for genetic obesity drugs is expected to witness growth across regions with a high prevalence of obesity, such as North America, Europe, and the Asia Pacific. These regions have well-established healthcare infrastructure and research capabilities, which contribute to advancements in genetic obesity treatment options.
Key players in the global genetic obesity drug market include pharmaceutical companies, biotechnology firms, and research institutions. These entities are actively involved in research and development efforts to identify novel drug targets, explore gene-based therapies, and conduct clinical trials.
It’s important to note that the development and approval of drugs for genetic obesity are complex processes that involve rigorous testing, regulatory approvals, and extensive research. The timeline for the availability of specific genetic obesity drugs may vary based on the stage of development and regulatory requirements.
In summary, the global genetic obesity drug market is in its early stages of development. Although there are currently limited approved medications targeted towards genetic obesity, ongoing research and advancements in genetic understanding hold promise for the future. As research progresses and personalized treatment approaches emerge, the market for genetic obesity drugs may expand, offering new treatment options for individuals affected by genetic forms of obesity.
The Global Info Research report includes an overview of the development of the Genetic Obesity Drug industry chain, the market status of Hospitals Pharmacy (Sibutramine, Orlistat), Retail Pharmacy (Sibutramine, Orlistat), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Genetic Obesity Drug.
Regionally, the report analyzes the Genetic Obesity Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Genetic Obesity Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Genetic Obesity Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Genetic Obesity Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Sibutramine, Orlistat).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Genetic Obesity Drug market.
Regional Analysis: The report involves examining the Genetic Obesity Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Genetic Obesity Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Genetic Obesity Drug:
Company Analysis: Report covers individual Genetic Obesity Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Genetic Obesity Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals Pharmacy, Retail Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Genetic Obesity Drug. It assesses the current state, advancements, and potential future developments in Genetic Obesity Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Genetic Obesity Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Genetic Obesity Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others
Market segment by Application
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Market segment by players, this report covers
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Genetic Obesity Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Genetic Obesity Drug, with revenue, gross margin and global market share of Genetic Obesity Drug from 2018 to 2023.
Chapter 3, the Genetic Obesity Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Genetic Obesity Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Genetic Obesity Drug.
Chapter 13, to describe Genetic Obesity Drug research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Genetic Obesity Drug
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Genetic Obesity Drug by Type
1.3.1 Overview: Global Genetic Obesity Drug Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Genetic Obesity Drug Consumption Value Market Share by Type in 2022
1.3.3 Sibutramine
1.3.4 Orlistat
1.3.5 Sympathomimetic Drugs
1.3.6 Receptors Antagonists
1.3.7 Others
1.4 Global Genetic Obesity Drug Market by Application
1.4.1 Overview: Global Genetic Obesity Drug Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals Pharmacy
1.4.3 Retail Pharmacy
1.4.4 Online Pharmacy
1.4.5 Others
1.5 Global Genetic Obesity Drug Market Size & Forecast
1.6 Global Genetic Obesity Drug Market Size and Forecast by Region
1.6.1 Global Genetic Obesity Drug Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Genetic Obesity Drug Market Size by Region, (2018-2029)
1.6.3 North America Genetic Obesity Drug Market Size and Prospect (2018-2029)
1.6.4 Europe Genetic Obesity Drug Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Genetic Obesity Drug Market Size and Prospect (2018-2029)
1.6.6 South America Genetic Obesity Drug Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Genetic Obesity Drug Market Size and Prospect (2018-2029)
2.1 Pfizer, Inc.
2.1.1 Pfizer, Inc. Details
2.1.2 Pfizer, Inc. Major Business
2.1.3 Pfizer, Inc. Genetic Obesity Drug Product and Solutions
2.1.4 Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer, Inc. Recent Developments and Future Plans
2.2 Sanofi.
2.2.1 Sanofi. Details
2.2.2 Sanofi. Major Business
2.2.3 Sanofi. Genetic Obesity Drug Product and Solutions
2.2.4 Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Sanofi. Recent Developments and Future Plans
2.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
2.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Details
2.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
2.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Solutions
2.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.4 Biocon.
2.4.1 Biocon. Details
2.4.2 Biocon. Major Business
2.4.3 Biocon. Genetic Obesity Drug Product and Solutions
2.4.4 Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biocon. Recent Developments and Future Plans
2.5 Adocia
2.5.1 Adocia Details
2.5.2 Adocia Major Business
2.5.3 Adocia Genetic Obesity Drug Product and Solutions
2.5.4 Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Adocia Recent Developments and Future Plans
2.6 GlaxoSmithKline Plc.
2.6.1 GlaxoSmithKline Plc. Details
2.6.2 GlaxoSmithKline Plc. Major Business
2.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Product and Solutions
2.6.4 GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 GlaxoSmithKline Plc. Recent Developments and Future Plans
2.7 Novo Nordisk A/S.
2.7.1 Novo Nordisk A/S. Details
2.7.2 Novo Nordisk A/S. Major Business
2.7.3 Novo Nordisk A/S. Genetic Obesity Drug Product and Solutions
2.7.4 Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novo Nordisk A/S. Recent Developments and Future Plans
2.8 Oramed Pharmaceuticals, Inc
2.8.1 Oramed Pharmaceuticals, Inc Details
2.8.2 Oramed Pharmaceuticals, Inc Major Business
2.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Solutions
2.8.4 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Oramed Pharmaceuticals, Inc Recent Developments and Future Plans
2.9 Wockhardt.
2.9.1 Wockhardt. Details
2.9.2 Wockhardt. Major Business
2.9.3 Wockhardt. Genetic Obesity Drug Product and Solutions
2.9.4 Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Wockhardt. Recent Developments and Future Plans
2.10 Eli Lilly and Company.
2.10.1 Eli Lilly and Company. Details
2.10.2 Eli Lilly and Company. Major Business
2.10.3 Eli Lilly and Company. Genetic Obesity Drug Product and Solutions
2.10.4 Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Eli Lilly and Company. Recent Developments and Future Plans
2.11 Merck & Co., Inc.
2.11.1 Merck & Co., Inc. Details
2.11.2 Merck & Co., Inc. Major Business
2.11.3 Merck & Co., Inc. Genetic Obesity Drug Product and Solutions
2.11.4 Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Merck & Co., Inc. Recent Developments and Future Plans
2.12 Julphar.
2.12.1 Julphar. Details
2.12.2 Julphar. Major Business
2.12.3 Julphar. Genetic Obesity Drug Product and Solutions
2.12.4 Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Julphar. Recent Developments and Future Plans
2.13 Bristol-Myers Squibb Company.
2.13.1 Bristol-Myers Squibb Company. Details
2.13.2 Bristol-Myers Squibb Company. Major Business
2.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Solutions
2.13.4 Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bristol-Myers Squibb Company. Recent Developments and Future Plans
3.1 Global Genetic Obesity Drug Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Genetic Obesity Drug by Company Revenue
3.2.2 Top 3 Genetic Obesity Drug Players Market Share in 2022
3.2.3 Top 6 Genetic Obesity Drug Players Market Share in 2022
3.3 Genetic Obesity Drug Market: Overall Company Footprint Analysis
3.3.1 Genetic Obesity Drug Market: Region Footprint
3.3.2 Genetic Obesity Drug Market: Company Product Type Footprint
3.3.3 Genetic Obesity Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Genetic Obesity Drug Consumption Value and Market Share by Type (2018-2023)
4.2 Global Genetic Obesity Drug Market Forecast by Type (2024-2029)
5.1 Global Genetic Obesity Drug Consumption Value Market Share by Application (2018-2023)
5.2 Global Genetic Obesity Drug Market Forecast by Application (2024-2029)
6.1 North America Genetic Obesity Drug Consumption Value by Type (2018-2029)
6.2 North America Genetic Obesity Drug Consumption Value by Application (2018-2029)
6.3 North America Genetic Obesity Drug Market Size by Country
6.3.1 North America Genetic Obesity Drug Consumption Value by Country (2018-2029)
6.3.2 United States Genetic Obesity Drug Market Size and Forecast (2018-2029)
6.3.3 Canada Genetic Obesity Drug Market Size and Forecast (2018-2029)
6.3.4 Mexico Genetic Obesity Drug Market Size and Forecast (2018-2029)
7.1 Europe Genetic Obesity Drug Consumption Value by Type (2018-2029)
7.2 Europe Genetic Obesity Drug Consumption Value by Application (2018-2029)
7.3 Europe Genetic Obesity Drug Market Size by Country
7.3.1 Europe Genetic Obesity Drug Consumption Value by Country (2018-2029)
7.3.2 Germany Genetic Obesity Drug Market Size and Forecast (2018-2029)
7.3.3 France Genetic Obesity Drug Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Genetic Obesity Drug Market Size and Forecast (2018-2029)
7.3.5 Russia Genetic Obesity Drug Market Size and Forecast (2018-2029)
7.3.6 Italy Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.1 Asia-Pacific Genetic Obesity Drug Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Genetic Obesity Drug Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Genetic Obesity Drug Market Size by Region
8.3.1 Asia-Pacific Genetic Obesity Drug Consumption Value by Region (2018-2029)
8.3.2 China Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.3.3 Japan Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.3.4 South Korea Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.3.5 India Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Genetic Obesity Drug Market Size and Forecast (2018-2029)
8.3.7 Australia Genetic Obesity Drug Market Size and Forecast (2018-2029)
9.1 South America Genetic Obesity Drug Consumption Value by Type (2018-2029)
9.2 South America Genetic Obesity Drug Consumption Value by Application (2018-2029)
9.3 South America Genetic Obesity Drug Market Size by Country
9.3.1 South America Genetic Obesity Drug Consumption Value by Country (2018-2029)
9.3.2 Brazil Genetic Obesity Drug Market Size and Forecast (2018-2029)
9.3.3 Argentina Genetic Obesity Drug Market Size and Forecast (2018-2029)
10.1 Middle East & Africa Genetic Obesity Drug Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Genetic Obesity Drug Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Genetic Obesity Drug Market Size by Country
10.3.1 Middle East & Africa Genetic Obesity Drug Consumption Value by Country (2018-2029)
10.3.2 Turkey Genetic Obesity Drug Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Genetic Obesity Drug Market Size and Forecast (2018-2029)
10.3.4 UAE Genetic Obesity Drug Market Size and Forecast (2018-2029)
11.1 Genetic Obesity Drug Market Drivers
11.2 Genetic Obesity Drug Market Restraints
11.3 Genetic Obesity Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Genetic Obesity Drug Industry Chain
12.2 Genetic Obesity Drug Upstream Analysis
12.3 Genetic Obesity Drug Midstream Analysis
12.4 Genetic Obesity Drug Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Genetic Obesity Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Genetic Obesity Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Genetic Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Genetic Obesity Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Pfizer, Inc. Company Information, Head Office, and Major Competitors
Table 6. Pfizer, Inc. Major Business
Table 7. Pfizer, Inc. Genetic Obesity Drug Product and Solutions
Table 8. Pfizer, Inc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Pfizer, Inc. Recent Developments and Future Plans
Table 10. Sanofi. Company Information, Head Office, and Major Competitors
Table 11. Sanofi. Major Business
Table 12. Sanofi. Genetic Obesity Drug Product and Solutions
Table 13. Sanofi. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Sanofi. Recent Developments and Future Plans
Table 15. Tonghua Dongbao Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 16. Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
Table 17. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Solutions
Table 18. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 20. Biocon. Company Information, Head Office, and Major Competitors
Table 21. Biocon. Major Business
Table 22. Biocon. Genetic Obesity Drug Product and Solutions
Table 23. Biocon. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biocon. Recent Developments and Future Plans
Table 25. Adocia Company Information, Head Office, and Major Competitors
Table 26. Adocia Major Business
Table 27. Adocia Genetic Obesity Drug Product and Solutions
Table 28. Adocia Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Adocia Recent Developments and Future Plans
Table 30. GlaxoSmithKline Plc. Company Information, Head Office, and Major Competitors
Table 31. GlaxoSmithKline Plc. Major Business
Table 32. GlaxoSmithKline Plc. Genetic Obesity Drug Product and Solutions
Table 33. GlaxoSmithKline Plc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. GlaxoSmithKline Plc. Recent Developments and Future Plans
Table 35. Novo Nordisk A/S. Company Information, Head Office, and Major Competitors
Table 36. Novo Nordisk A/S. Major Business
Table 37. Novo Nordisk A/S. Genetic Obesity Drug Product and Solutions
Table 38. Novo Nordisk A/S. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novo Nordisk A/S. Recent Developments and Future Plans
Table 40. Oramed Pharmaceuticals, Inc Company Information, Head Office, and Major Competitors
Table 41. Oramed Pharmaceuticals, Inc Major Business
Table 42. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Solutions
Table 43. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Oramed Pharmaceuticals, Inc Recent Developments and Future Plans
Table 45. Wockhardt. Company Information, Head Office, and Major Competitors
Table 46. Wockhardt. Major Business
Table 47. Wockhardt. Genetic Obesity Drug Product and Solutions
Table 48. Wockhardt. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Wockhardt. Recent Developments and Future Plans
Table 50. Eli Lilly and Company. Company Information, Head Office, and Major Competitors
Table 51. Eli Lilly and Company. Major Business
Table 52. Eli Lilly and Company. Genetic Obesity Drug Product and Solutions
Table 53. Eli Lilly and Company. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Eli Lilly and Company. Recent Developments and Future Plans
Table 55. Merck & Co., Inc. Company Information, Head Office, and Major Competitors
Table 56. Merck & Co., Inc. Major Business
Table 57. Merck & Co., Inc. Genetic Obesity Drug Product and Solutions
Table 58. Merck & Co., Inc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Merck & Co., Inc. Recent Developments and Future Plans
Table 60. Julphar. Company Information, Head Office, and Major Competitors
Table 61. Julphar. Major Business
Table 62. Julphar. Genetic Obesity Drug Product and Solutions
Table 63. Julphar. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Julphar. Recent Developments and Future Plans
Table 65. Bristol-Myers Squibb Company. Company Information, Head Office, and Major Competitors
Table 66. Bristol-Myers Squibb Company. Major Business
Table 67. Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Solutions
Table 68. Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Bristol-Myers Squibb Company. Recent Developments and Future Plans
Table 70. Global Genetic Obesity Drug Revenue (USD Million) by Players (2018-2023)
Table 71. Global Genetic Obesity Drug Revenue Share by Players (2018-2023)
Table 72. Breakdown of Genetic Obesity Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 73. Market Position of Players in Genetic Obesity Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 74. Head Office of Key Genetic Obesity Drug Players
Table 75. Genetic Obesity Drug Market: Company Product Type Footprint
Table 76. Genetic Obesity Drug Market: Company Product Application Footprint
Table 77. Genetic Obesity Drug New Market Entrants and Barriers to Market Entry
Table 78. Genetic Obesity Drug Mergers, Acquisition, Agreements, and Collaborations
Table 79. Global Genetic Obesity Drug Consumption Value (USD Million) by Type (2018-2023)
Table 80. Global Genetic Obesity Drug Consumption Value Share by Type (2018-2023)
Table 81. Global Genetic Obesity Drug Consumption Value Forecast by Type (2024-2029)
Table 82. Global Genetic Obesity Drug Consumption Value by Application (2018-2023)
Table 83. Global Genetic Obesity Drug Consumption Value Forecast by Application (2024-2029)
Table 84. North America Genetic Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 85. North America Genetic Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 86. North America Genetic Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 87. North America Genetic Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 88. North America Genetic Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 89. North America Genetic Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 90. Europe Genetic Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Europe Genetic Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Europe Genetic Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 93. Europe Genetic Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 94. Europe Genetic Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Genetic Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Genetic Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 97. Asia-Pacific Genetic Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 98. Asia-Pacific Genetic Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 99. Asia-Pacific Genetic Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 100. Asia-Pacific Genetic Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 101. Asia-Pacific Genetic Obesity Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 102. South America Genetic Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 103. South America Genetic Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 104. South America Genetic Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 105. South America Genetic Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 106. South America Genetic Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 107. South America Genetic Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Middle East & Africa Genetic Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 109. Middle East & Africa Genetic Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 110. Middle East & Africa Genetic Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 111. Middle East & Africa Genetic Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 112. Middle East & Africa Genetic Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 113. Middle East & Africa Genetic Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 114. Genetic Obesity Drug Raw Material
Table 115. Key Suppliers of Genetic Obesity Drug Raw Materials
List of Figures
Figure 1. Genetic Obesity Drug Picture
Figure 2. Global Genetic Obesity Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Genetic Obesity Drug Consumption Value Market Share by Type in 2022
Figure 4. Sibutramine
Figure 5. Orlistat
Figure 6. Sympathomimetic Drugs
Figure 7. Receptors Antagonists
Figure 8. Others
Figure 9. Global Genetic Obesity Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Genetic Obesity Drug Consumption Value Market Share by Application in 2022
Figure 11. Hospitals Pharmacy Picture
Figure 12. Retail Pharmacy Picture
Figure 13. Online Pharmacy Picture
Figure 14. Others Picture
Figure 15. Global Genetic Obesity Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Genetic Obesity Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Market Genetic Obesity Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 18. Global Genetic Obesity Drug Consumption Value Market Share by Region (2018-2029)
Figure 19. Global Genetic Obesity Drug Consumption Value Market Share by Region in 2022
Figure 20. North America Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. Europe Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. Asia-Pacific Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. South America Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Middle East and Africa Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Global Genetic Obesity Drug Revenue Share by Players in 2022
Figure 26. Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 27. Global Top 3 Players Genetic Obesity Drug Market Share in 2022
Figure 28. Global Top 6 Players Genetic Obesity Drug Market Share in 2022
Figure 29. Global Genetic Obesity Drug Consumption Value Share by Type (2018-2023)
Figure 30. Global Genetic Obesity Drug Market Share Forecast by Type (2024-2029)
Figure 31. Global Genetic Obesity Drug Consumption Value Share by Application (2018-2023)
Figure 32. Global Genetic Obesity Drug Market Share Forecast by Application (2024-2029)
Figure 33. North America Genetic Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 34. North America Genetic Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 35. North America Genetic Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 37. Canada Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 38. Mexico Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 39. Europe Genetic Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 40. Europe Genetic Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 41. Europe Genetic Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 42. Germany Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 43. France Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 44. United Kingdom Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 45. Russia Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 46. Italy Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 47. Asia-Pacific Genetic Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 48. Asia-Pacific Genetic Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 49. Asia-Pacific Genetic Obesity Drug Consumption Value Market Share by Region (2018-2029)
Figure 50. China Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 51. Japan Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 52. South Korea Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 53. India Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 54. Southeast Asia Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 55. Australia Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 56. South America Genetic Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 57. South America Genetic Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 58. South America Genetic Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 59. Brazil Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 60. Argentina Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 61. Middle East and Africa Genetic Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 62. Middle East and Africa Genetic Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 63. Middle East and Africa Genetic Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 64. Turkey Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 65. Saudi Arabia Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 66. UAE Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 67. Genetic Obesity Drug Market Drivers
Figure 68. Genetic Obesity Drug Market Restraints
Figure 69. Genetic Obesity Drug Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Manufacturing Cost Structure Analysis of Genetic Obesity Drug in 2022
Figure 72. Manufacturing Process Analysis of Genetic Obesity Drug
Figure 73. Genetic Obesity Drug Industrial Chain
Figure 74. Methodology
Figure 75. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pfizer, Inc. Sanofi. Tonghua Dongbao Pharmaceutical Co., Ltd. Biocon. Adocia GlaxoSmithKline Plc. Novo Nordisk A/S. Oramed Pharmaceuticals, Inc Wockhardt. Eli Lilly and Company. Merck & Co., Inc. Julphar. Bristol-Myers Squibb Company.
Related Reports
02 Sep 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
